Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

Thank you for posting this. Hope it is

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jfk Member Profile
 
Followed By 2
Posts 246
Boards Moderated 0
Alias Born 05/10/07
160x600 placeholder
BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled GlobeNewswire Inc. - 10/11/2019 1:00:00 AM
BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform GlobeNewswire Inc. - 10/7/2019 8:04:26 AM
BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 1... GlobeNewswire Inc. - 10/2/2019 6:45:00 AM
BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development GlobeNewswire Inc. - 9/27/2019 4:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 8:01:47 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 8:01:32 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/9/2019 8:01:03 AM
BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financi... GlobeNewswire Inc. - 9/9/2019 1:00:00 AM
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress GlobeNewswire Inc. - 9/6/2019 1:50:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/3/2019 6:01:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2019 5:03:19 PM
Prospectus Filed Pursuant to Rule 424(b)(1) (424b1) Edgar (US Regulatory) - 8/30/2019 5:02:28 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/16/2019 5:18:25 PM
BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update GlobeNewswire Inc. - 8/13/2019 7:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/13/2019 6:05:47 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 8/9/2019 5:10:20 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update GlobeNewswire Inc. - 8/5/2019 1:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/2/2019 5:02:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2019 9:30:43 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/26/2019 5:04:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/26/2019 5:04:06 PM
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study GlobeNewswire Inc. - 7/2/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/11/2019 5:03:07 PM
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting GlobeNewswire Inc. - 5/31/2019 1:00:00 AM
jfk   Tuesday, 03/19/19 08:08:01 PM
Re: Chief-money post# 2480
Post # of 2560 
Thank you for posting this. Hope it is true. They should be able to create some groundswell in other international ALS organizations for a Right to Try there as well.
The Hospital Exemption Program in Israel is an excellent start. It was easily predicted to begin there with this model, but the company was extremely closed lipped about it. Hoping that Canada (Brazil?) and other countries might be willing to duplicate the model. You'll never hear it from BCLI until the news is formally issued via PR.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist